A Single Ascending Dose, Open-Label Study Evaluating the Safety, Tolerability, And Pharmacokinetics of ALA-1000 in Opioid-Dependent Individuals
Latest Information Update: 19 Jan 2022
At a glance
- Drugs Buprenorphine (Primary) ; Buprenorphine
- Indications Opioid-related disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Alar Pharmaceuticals
Most Recent Events
- 12 Jan 2022 Positive results published in an Alar Pharmaceuticals Media Release.
- 28 Dec 2021 Status changed from active, no longer recruiting to completed.
- 28 Apr 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.